We are monitoring the impact of COVID-19 on MEA Gastroparesis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 5078
Share on
Share on

MEA Gastroparesis Drugs Market Research Report – Segmented By Drug Class, Disease Type, End User and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends and Growth Forecast (2020 to 2025)

Pulished: February, 2020
ID: 5078
Pages: 145

The size of the Middle East and Africa Gastroparesis Drugs market was around USD 420 million in 2020. It is expected to grow at a CAGR of 3.8% to reach USD 500 million by 2025. It captures 8% of the global market.

Normal spontaneous movements of the muscles in the stomach are affected when a person is suffering from Gastroparesis often causing vomiting, improper digestion etc. Erythromycin, reglan are few drugs prescribed for the treatment. Augmenting geriatric population, increased number of surgeries causing Gastroparesis as a side effect, growing number of people with diabetes, and introduction of new drugs in the market for controlling symptoms like nausea are the major factors driving the growth of this market.

Negative side effects of prescribed drugs, inordinate delays in regulatory approvals, and complicated diagnostic procedure are the major factors inhibiting market growth.

The market is segmented by drug type, disease class and end user. Classification by drug type entails Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections. Classification by disease class entails Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others. Idiopathic Gastroparesis lead the market in 2020 and will retain its position till 2025. Its causes are unknown. However, this condition can be managed by dietary management. Classification by end user entails Hospitals, Pharmacies, Clinics, and E-commerce.

Classification by geography entails Middle East and Africa. MEA are poised for a robust growth in the forecast period due to increased investments by major companies in the market.

Key players in the market are Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods                          

               1.4 General Study Assumptions                 

2. Research Methodology                                          

               2.1 Introduction                             

               2.2 Research Phases                      

                              2.2.1 Secondary Research           

                              2.2.2 Primary Research 

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview                                     

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology                            

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                                            

               5.1 Drug Class                  

                              5.1.1 Introduction           

                              5.1.2 Prokinetic Agents 

                              5.1.3 Antiemetic Agents

                              5.1.4 Botulinum Toxin Injections              

                              5.1.5  Y-o-Y Growth Analysis, By Drug Class          

                              5.1.6  Market Attractiveness Analysis, By Drug Class        

                              5.1.7  Market Share Analysis, By Drug Class         

               5.2 Disease Type                            

                              5.2.1 Introduction           

                              5.2.2 Diabetic Gastroparesis       

                              5.2.3 Idiopathic Gastroparesis    

                              5.2.4 Post-surgical Gastroparesis              

                              5.2.5 Others      

                              5.2.6 Y-o-Y Growth Analysis, By Disease Type      

                              5.2.7 Market Attractiveness Analysis, By Disease Type    

                              5.2.8 Market Share Analysis, By Disease Type     

               5.3 End User                     

                              5.3.1 Introduction           

                              5.3.2 Hospitals  

                              5.3.3 Pharmacies             

                              5.3.4 Clinics       

                              5.3.5 E-commerce          

                              5.3.6 Y-o-Y Growth Analysis, By End User             

                              5.3.7 Market Attractiveness Analysis, By End User            

                              5.3.8 Market Share Analysis, By End User             

6. Geographical Analysis                                            

               6.1 Introduction                             

                              6.1.1 Regional Trends    

                              6.1.2 Impact Analysis     

                              6.1.3 Y-o-Y Growth Analysis        

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By Drug Class

                                             6.1.3.3 By Disease Type

                                             6.1.3.4 By End User

                              6.1.4  Market Attractiveness Analysis      

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By Drug Class

                                             6.1.4.3 By Disease Type

                                             6.1.4.4 By End User

                              6.1.5  Market Share Analysis       

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By Drug Class

                                             6.1.5.3 By Disease Type

                                             6.1.5.4 By End User

               6.2 Middle-East                              

               6.3 Africa                          

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis                             

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services

                              7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis                                       

               8.1 Allergan, Plc.                            

                              8.1.1 Overview 

                              8.1.2 Product Analysis   

                              8.1.3 Financial analysis  

                              8.1.4 Recent Developments        

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View          

               8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)                      

               8.3 AstraZeneca Plc.                      

               8.4 Cadila Pharmaceuticals Ltd.                

               8.5 ETX Pharma, Inc                      

               8.6 Evoke Pharma                          

               8.7 GlaxoSmithKline Plc.                             

               8.8 Neurogastrx, Inc.                    

               8.9 Valeant Pharmaceuticals International, Inc.                 

               8.10 Theravance Biopharma                      

9. Competitive Landscape                                         

               9.1 Market share analysis                           

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures                          

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                          

               a) List of Tables                

               b) List of Figures                             

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East and Africa Gastroparesis Drugs Market, By Drug Class, From 2020 to 2025 (USD Billion)
  2. Middle East and Africa Prokinetic Agents Market, By Region, From 2020 to 2025 (USD Billion)
  3. Middle East and Africa Antiemetic Agents Market, By Region, From 2020 to 2025 (USD Billion)
  4. Middle East and Africa Botulinum Toxin Injections Market, By Region, From 2020 to 2025 (USD Billion)
  5. Middle East and Africa Gastroparesis Drugs Market, By Disease Type, From 2020 to 2025 (USD Billion)
  6. Middle East and Africa Diabetic Gastroparesis Market, By Region, From 2020 to 2025 (USD Billion)
  7. Middle East and Africa Idiopathic Gastroparesis Market, By Region, From 2020 to 2025 (USD Billion)
  8. Middle East and Africa Post-surgical Gastroparesis Market, By Region, From 2020 to 2025 (USD Billion)
  9. Middle East and Africa Others Market, By Region, From 2020 to 2025 (USD Billion)
  10. Middle East and Africa Gastroparesis Drugs Market, By End User, From 2020 to 2025 (USD Billion)
  11. Middle East and Africa Hospitals Market, By Region, From 2020 to 2025 (USD Billion)
  12. Middle East and Africa Pharmacies Market, By Region, From 2020 to 2025 (USD Billion)
  13. Middle East and Africa Clinics Market, By Region, From 2020 to 2025 (USD Billion)
  14. Middle East and Africa E-commerce Market, By Region, From 2020 to 2025 (USD Billion)
  15. Middle East Gastroparesis Drugs Market, By Drug Class, From 2020 to 2025 (USD Billion)
  16. Middle East Gastroparesis Drugs Market, By Disease Type, From 2020 to 2025 (USD Billion)
  17. Middle East Gastroparesis Drugs Market, By End User, From 2020 to 2025 (USD Billion)
  18. Africa Gastroparesis Drugs Market, By Drug Class, From 2020 to 2025 (USD Billion)
  19. Africa Gastroparesis Drugs Market, By Disease Type, From 2020 to 2025 (USD Billion)
  20. Africa Gastroparesis Drugs Market, By End User, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample